Cingulate Inc.

CING ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item Jun 2026 Mar 2026 Dec 2025 Sep 2025 Jun 2025 Mar 2025 Dec 2024 Sep 2024
Operating Activities
Net Income $-5.9M $-9.3M $-6.3M $-7.3M $-5.0M $-3.9M $-6.2M $-4.1M
Depreciation & Amortization — — — — — — — —
Depreciation $98.2K $121.2K $121.8K $106.8K $147.0K $165.3K $160.3K $165.4K
Amortization — — — — — — — —
Stock-Based Compensation $362.2K $593.1K $386.0K $592.8K $187.4K $357.6K $60.3K $393.8K
Net Cash from Operating Activities $-5.9M $-6.9M $-3.6M $-4.2M $-4.8M $-4.6M $-4.1M $-3.9M
Investing Activities
Capital Expenditures $67.1K $61.2K — — — — $198.5K $-140.8K
Business Acquisitions — — — — — — — —
Net Cash from Investing Activities $-67.1K $-61.2K — — — — $-198.5K $140.8K
Financing Activities
Dividends Paid — — — — — — — —
Stock Repurchases — — — — — — — —
Net Cash from Financing Activities $8.5M $21.9M $8.6M $1.5M $4.2M $1.9M $6.4M $13.4M
Net Change in Cash $2.5M $14.9M $4.8M $-2.8M $-618.8K $-2.7M $2.2M $9.7M
Free Cash Flow $-6.0M $-7.0M — — — — $-4.3M $-3.7M
← Newer Page 1 of 3 Older →